TRENDING
PharmaBro Sues RZA, Says He’s Supposed To Own Album Until He’s 120-Years-Old
Published
3 months agoon
By
Mike Winslow

Martin Shkreli just threw a legal curveball at the people who bought Wu-Tang Clan’s one-of-a-kind album.
The former pharma exec filed a countersuit Monday night in Brooklyn federal court. He’s going after PleasrDAO, the digital art collective that paid $4 million for Once Upon a Time in Shaolin.
But he’s also targeting Wu-Tang’s RZA and producer Cilvaringz.
Shkreli claims he still owns 50% of the album’s copyrights. His argument? The original 2015 contract states that his copyright stake reverts to him in 2103. That’s when he’d be 120 years old.
“The defendants violated his rights when PleasrDAO paid RZA and Cilvaringz $750,000 for that stake,” Shkreli’s legal team wrote. They say RZA and Cilvaringz basically sold “a total of 150% of the copyrights.”
That math doesn’t add up if Shkreli really owns half. PleasrDAO’s lawyer Steven Cooper isn’t buying it.
“Mr. Shkreli’s approach throughout has been to distract and delay with actions that the court has consistently and strenuously rejected,” Cooper said in an email to The Daily Record. “These counterclaims will meet the same fate.”
This whole saga started when PleasrDAO sued Shkreli in June 2024. They accused him of keeping copies of the album and livestreaming parts of it to his followers.
The collective said he violated his 2015 sale contract by doing that.
Shkreli originally bought the album for $1.5 million in 2015. But he had to give it up in 2017 after his conviction for defrauding hedge fund investors and scheming to defraud investors in his drugmaker Retrophin.
The government sold the album to PleasrDAO for about $4 million in 2021.
Last September, U.S. District Judge Pamela Chen allowed PleasrDAO’s lawsuit to proceed. She said the album’s value comes from the collective’s “ability to exploit its exclusivity to create an ‘experience’ that its competitors cannot.”
But now Shkreli is fighting back. He wants unspecified damages and profits from RZA, Cilvaringz, and PleasrDAO.
Shkreli became known as “Pharma Bro” in 2015 when he jacked up the price of the life-saving drug Daraprim from $17.50 to $750 per tablet overnight.
He was released from prison early in 2022 and is banned from the pharmaceutical industry.
Related
Mike Winslow
Source link
Lizzo Explains Why She Named Her Album “Bitch”
Why Key & Peele No Longer Work Together…Allegedly!
WNBA Guard Lexie Brown Denies She Wrecked Megan Thee Stallion’s Relationship With Klay Thompson
Machine Gun Kelly Cocaine Bust Keeps Him Stuck In Airport Lines
GloRilla Annoys Brandon Ingram Into Exhaustion Before NBA Matchup
Exclusive Interview With Positive Society
Exclusive Interview with Robert Flournoy
Exclusive Interview with Humble Hefe
Exclusive Interview with Christian K
Exclusive interview with Hefe OG
Cardi B – Bongos (feat. Megan Thee Stallion) [Official Music Video]
Travis Scott – KICK OUT
Kevin Gates – F*k Em (Official Music Video)
Enphamus – No Biggie 2 ft Big Yavo (Official Video)
Rod Wave – Feed The Streets (Official Music Video)
TRENDING
Lizzo Explains Why She Named Her Album “Bitch”
Lizzo’s turning “B####” into a declaration of power with her new album dropping June 5, reclaiming the word as unapologetic...
Why Key & Peele No Longer Work Together…Allegedly!
Akilah Hughes claims a promising Disney sketch show may explain why Keegan-Michael Key and Jordan Peele no longer work together....
WNBA Guard Lexie Brown Denies She Wrecked Megan Thee Stallion’s Relationship With Klay Thompson
WNBA guard Lexie Brown publicly denies any involvement in Klay Thompson’s breakup with Megan Thee Stallion after internet rumors spiraled...
Machine Gun Kelly Cocaine Bust Keeps Him Stuck In Airport Lines
Machine Gun Kelly reveals a past cocaine charge keeps him banned from TSA PreCheck and stuck in regular airport lines...
GloRilla Annoys Brandon Ingram Into Exhaustion Before NBA Matchup
Brandon Ingram reveals his girlfriend GloRilla’s unique way of helping him rest before big games. GloRilla knows exactly how to...
